Significance of coagulation and fibrinolysis markers for benign and malignant soft tissue tumors.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Biomarkers/*blood ; Blood Coagulation/*genetics ; Fibrinolysis/*genetics ; Soft Tissue Neoplasms/*genetics; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Female ; Humans ; Male ; Middle Aged ; Young Adult

Background: The intimate relationship between coagulation and fibrinolysis in malignant tumors is a well-known phenomena, with the malignant phenotype enhancing coagulation and fibrinolysis. We hypothesized that soft tissue sarcoma (STS) affects the expression of coagulation and fibrinolysis markers, which could be used to distinguish STS from benign soft tissue tumors. We analyzed the correlations between plasma levels of D-dimer (DD), plasmin-α2 plasmin inhibitor complex (PIC), soluble fibrin (SF), and thrombin-antithrombin III complex (TAT) in benign soft tissue tumors and STS to elucidate whether these markers can be used to predict STS.
Methods: Plasma DD, PIC, SF and TAT levels in primary soft tissue tumors (benign 67, STS 68) were measured before biopsy or treatment. The marker levels were analyzed and compared to various clinicopathological parameters.
Results: In malignancy (STS), the average DD, PIC and SF levels were significantly higher than in benign tumors. Multivariate logistic analysis of continuous variables indicated that only PIC exhibited a significant difference (OR: 24.5, 95%CI: 3.55-170, p = 0.0012). Receiver operating characteristic curve analysis produced area under the curve values for DD: 0.691, PIC: 0.784, SF: 0.734 and TAT: 0.588. Youden's index was used to establish thresholds of 0.37 (DD), 0.80 (PIC), 0.90 (SF) and 0.82 (TAT). Threshold values for PIC and SF indicated high specificity (0.881, 0.791) and high positive predictive value (0.818, 0.745), respectively. The highest accuracy value among the markers was observed for PIC (0.704). Significant differences in multivariate analysis of binary variables were demonstrated by categorizing low and high groups based on their threshold, PIC (≥0.80) (OR: 3.36, 95%CI: 1.19-9.43, p = 0.0212) and SF (≥0.90) (OR: 2.63, 95%CI: 1.04-6.66, p = 0.0404) .
Conclusions: Of the coagulation and fibrinolysis markers studied, increased PIC levels were related to STS and over 0.80 PIC was the most suitable for the prediction of STS, which, along with other diagnostic tools, represents a helpful subsidiary tool for the prediction of STS.

Urol Oncol. 2014 Oct;32(7):1031-40. (PMID: 25027687)
Respir Med. 2013 Mar;107(3):451-7. (PMID: 23200643)
Cancer Biomark. 2016;16(3):453-8. (PMID: 27062702)
Tumori. 1998 May-Jun;84(3):364-7. (PMID: 9678618)
Am J Clin Oncol. 2015 Dec;38(6):550-6. (PMID: 24401666)
Bone Marrow Transplant. 2013 Mar;48(3):452-8. (PMID: 23208313)
J Cell Biol. 1989 May;108(5):1987-95. (PMID: 2523891)
Colorectal Dis. 2008 Mar;10(3):238-41. (PMID: 17868411)
Tumour Biol. 2014 Jun;35(6):5985-92. (PMID: 24596033)
Clin Genitourin Cancer. 2020 Feb;18(1):11-19.e1. (PMID: 31787543)
J Med Assoc Thai. 2013 Nov;96(11):1395-400. (PMID: 24428087)
Anticancer Res. 2014 Sep;34(9):5181-5. (PMID: 25202112)
Haematologica. 2012 Aug;97(8):1158-64. (PMID: 22371182)
Eur Radiol. 2016 Dec;26(12):4640-4648. (PMID: 26960540)
J BUON. 2017 Mar-Apr;22(2):462-467. (PMID: 28534370)
Med Princ Pract. 2013;22(1):4-11. (PMID: 22584792)
Thromb Res. 2020 Feb;186:80-85. (PMID: 31918352)
Cancer Metastasis Rev. 1992 Nov;11(3-4):291-311. (PMID: 1423820)
Scand J Clin Lab Invest. 1998 Nov;58(7):555-9. (PMID: 9890338)
Oncotarget. 2017 May 16;8(31):51551-51558. (PMID: 28881667)
Blood. 1996 Sep 15;88(6):2109-17. (PMID: 8822930)
Br J Cancer. 2010 Feb 16;102(4):731-7. (PMID: 20051950)
Cancer Biomark. 2015;15(4):405-11. (PMID: 25792472)
Clin Sarcoma Res. 2012 Oct 04;2(1):14. (PMID: 23036164)
Clin Chim Acta. 2018 Jul;482:191-198. (PMID: 29649456)
Medicine (Baltimore). 2020 Feb;99(7):e19243. (PMID: 32049865)

Keywords: And thrombin-antithrombin III complex; Coagulation; D-dimer; Fibrinolysis; Metastasis; Plasmin-α2 plasmin inhibitor complex; Prognosis; Soft tissue sarcoma; Soluble fibrin

0 (Biomarkers)

Date Created: 20210408 Date Completed: 20210517 Latest Revision: 20210517

20240829

PMC8028118

10.1186/s12885-021-08091-1

33827473